ARTICLE | Clinical News
Bavituximab: Phase II data
January 16, 2012 8:00 AM UTC
An open-label Phase II trial in 66 treatment-naive patients with HCV genotype 1 infection showed that 0.3 or 3 mg/kg bavituximab plus ribavirin had fewer side effects compared with standard of care (S...